SCHEMBL2798264

SCHEMBL2798264

CCCCCCCCCCCCCCCCCC[C@@H](C)C=C(C)C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
LCK P06239 1/20 0.48
PPARD Q03181 1/20 0.48
ZDHHC20 Q5W0Z9 1/20 0.48
ZDHHC2 Q9UIJ5 1/20 0.48
ACE2 Q9BYF1 1/20 0.46
GPR84 Q9NQS5 7/20 0.46
FFAR1 O14842 2/20 0.46
ZDHHC7 Q9NXF8 1/20 0.44
MAPT P10636 1/20 0.44
FAAH O00519 1/20 0.42
FFAR4 Q5NUL3 1/20 0.42
CA1 P00915 2/20 0.41
EP300 Q09472 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10386189 1.00 LCK (0.48) LCKPPARDZDHHC20ZDHHC2ACE2
SCHEMBL5362188 1.00 LCK (0.48) LCKPPARDZDHHC20ZDHHC2ACE2
SCHEMBL2798260 1.00 LCK (0.48) LCKPPARDZDHHC20ZDHHC2ACE2
SCHEMBL5362193 1.00 LCK (0.48) LCKPPARDZDHHC20ZDHHC2ACE2
SCHEMBL16059073 1.00 LCK (0.48) LCKPPARDZDHHC20ZDHHC2ACE2
SCHEMBL2799138 1.00 LCK (0.48) LCKPPARDZDHHC20ZDHHC2ACE2
SCHEMBL16059072 1.00 LCK (0.48) LCKPPARDZDHHC20ZDHHC2ACE2
SCHEMBL15791893 1.00 LCK (0.48) LCKPPARDZDHHC20ZDHHC2ACE2
SCHEMBL10386188 1.00 LCK (0.48) LCKPPARDZDHHC20ZDHHC2ACE2
SCHEMBL28895769 1.00 LCK (0.48) LCKPPARDZDHHC20ZDHHC2ACE2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2125849-B1 SULFOGLYCOLIPID ANTIGENS, THEIR PROCESS OF PREPARATION, AND THEIR USE AGAINST TUBERCULOSIS CENTRE NAT DE LA RECH SCIENT (C N R S ) (FR) 2017-11-15 EP disclosed
US-8268801-B2 Sulfoglycolipid antigens, their process of preparation, and their use against tuberculosis CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) 2012-09-18 US disclosed
US-8268801-B2 Sulfoglycolipid antigens, their process of preparation, and their use against tuberculosis CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) 2012-09-18 US disclosed
US-20100166801-A1 SULFOGLYCOLIPID ANTIGENS, THEIR PROCESS OF PREPARATION, AND THEIR USE AGAINST TUBERCULOSIS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) 2010-07-01 US disclosed
US-20100166801-A1 SULFOGLYCOLIPID ANTIGENS, THEIR PROCESS OF PREPARATION, AND THEIR USE AGAINST TUBERCULOSIS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) 2010-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100166801-A1 SULFOGLYCOLIPID ANTIGENS, THEIR PROCESS OF PREPARATION, AND THEIR USE AGAINST TUBERCULOSIS FUT5, ALG1, FUT6 LCK 1263/4885PPARD 937/4885ZDHHC20 298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.